Screener
BridgeBio Pharma BBIO Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | Amortized Cost Basis | Unrealized Gains | Unrealized Losses | Estimated Fair Value |
|---|---|---|---|---|
| U.S. Treasury securities | 1,998 | — | — | 1,998 |
| Agency discount notes | 32,927 | — | (1) | 32,926 |
| Total cash equivalents | $378,538 | — | $(1) | $378,537 |
| Marketable securities: | ||||
| U.S. Treasury securities | 38,795 | — | (6) | 38,789 |
| Agency discount notes | 3,460 | — | — | 3,460 |
| Total marketable securities | 42,255 | — | (6) | 42,249 |
| Total cash equivalents and marketable securities | $420,793 | — | $(7) | $420,786 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's unrealized gains on investments?
- BridgeBio Pharma (BBIO) reported unrealized gains on investments of $0 in Q2 2026.
- What does unrealized gains on investments mean?
- The total unrealized gains on investments, typically related to available-for-sale securities.
Ask your AI about BridgeBio Pharma's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude